Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ben Man-Fai Chue
Observed names:
B Chue,
B. Chue,
B. M. Chue,
Ben Chue,
Ben M Chue,
Ben M. Chue
show all 6
Observed institutions:
Seattle Cancer Care Alliance,
University of Washington
OpenAlex ID:
A5006652575
Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
2018
·
Caroline E. McCoach
, Collin M. Blakely
, et al.
·
Clinical Cancer Research
·
152
Five-year survival of metastatic pancreatic carcinoma: a study of courage and hope.
2009
·
Ben M Chue
·
Europe PMC (PubMed Central)
·
19
Case report of long-term survival with metastatic triple-negative breast carcinoma
2019
·
Ben Man-Fai Chue
, Bryce Douglas La Course
·
Medicine
·
15
Can we cure stage IV triple-negative breast carcinoma?
2019
·
Ben Man-Fai Chue
, Bryce Douglas La Course
·
Medicine
·
5
A strategy to implement the American College of Sports Medicine’s Exercise is Medicine® (EIM) initiative in a community oncology clinic
2024
·
Eunjung Kim
, Catherine Duggan
, et al.
·
Supportive Care in Cancer
·
4
Sequential gemcitabine (G), oxaliplatin (O), and irinotecan (I) based weekly metronomic chemotherapy (MC) regimens for the treatment of metastatic pancreatic cancer (mPC): A community cancer clinic experience.
2019
·
Ben M. Chue
, Bryce D. La Course
·
Journal of Clinical Oncology
·
2
Eleven-Year Survival with Unresectable Metastatic PancreaticCarcinoma: A Roadmap to Long-term Survival for Metastatic Disease
2017
·
Ben M. Chue
, Bryce Douglas La Course
·
JOP, journal of the pancreas
·
2
Effects of a clinic-referred telemedical intervention to improve exercise uptake during chemotherapy
2025
·
Eunjung Kim
, Christian Helfrich
, et al.
·
Supportive Care in Cancer
·
1
Table 1 from Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
2023
·
Caroline E. McCoach
, Collin M. Blakely
, et al.
Supplementary Figures 1,2, 3 from Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
2023
·
Caroline E. McCoach
, Collin M. Blakely
, et al.
PDF
Data from Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
2023
·
Caroline E. McCoach
, Collin M. Blakely
, et al.
Data from Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
2023
·
Caroline E. McCoach
, Collin M. Blakely
, et al.
Table 1 from Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
2023
·
Caroline E. McCoach
, Collin M. Blakely
, et al.
PDF
Supplementary Figures 1,2, 3 from Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
2023
·
Caroline E. McCoach
, Collin M. Blakely
, et al.
Proof of concept: Weekly metronomic dosing of paclitaxel/gemcitabine (PaG) followed by paclitaxel/oxaliplatin/leucovorin/5-FU (POLF) for advanced stage pancreatic adenocarcinoma (PC)
2008
·
B. M. Chue
·
Journal of Clinical Oncology
Interim results of a weekly, metronomic dosing of paclitaxel, oxaliplatin, leucovorin, 5-FU (POLF) in the treatment of metastatic pancreatic cancer (PC)
2007
·
B. Chue
·
Journal of Clinical Oncology
Weekly paclitaxel, oxaliplatin, 5-FU and leucovorin in the treatment of metastatic pancreatic cancer
2006
·
B. Chue
, N. Chen
·
Journal of Clinical Oncology
Concerns over antioxidant-chemotherapy interactions overstated.
1999
·
P Reilly
, M Gignac
, et al.
·
PubMed
Show more works
View as search
Works count:
18
Citation count:
200
H-index:
4
I10-index:
3
Year
Topic
Type
